Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis
- Conditions
- Kidney Disease, Chronic
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 340
- Registration Number
- NCT01318512
- Locations
- 🇨🇿
Nemocnice Novy Jicin; Dialyzacni Stredisko, Novy Jicin, Czechia
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT01310036
- Locations
- 🇨🇳
Changhua Christian Hospital; Internal Medicine, Changhua, Taiwan
🇨🇳Veterans General Hospital; Internal Medicine, Kaohsiung, Taiwan
🇨🇳Chang Gung Medical Foundation - Linkou; Chest Dept, Taoyuan, Taiwan
Observational Study to Investigate the Long-term Effects of MIRCERA in Clinical Routine
- Conditions
- Anemia
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1083
- Registration Number
- NCT01309269
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease in Pre-Dialysis or Dialysis
- Conditions
- Anemia, Kidney Disease, Chronic
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 250
- Registration Number
- NCT01309295
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01309282
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01308723
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
- Conditions
- Glioblastoma Multiforme
- Interventions
- Drug: RO5323441 + bevacizumab [Avastin]
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT01308684
A Study of Vemurafenib in Participants With Metastatic Melanoma
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3219
- Registration Number
- NCT01307397
- Locations
- 🇦🇱
University "Mother Theresa" Hospital Center; Oncology Department, Tirana, Albania
🇦🇷Hospital Britanico; Oncologia, Buenos Aires, Argentina
🇦🇷Fundación CIDEA, Buenos Aires, Argentina
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
- Conditions
- Spinal Muscular Atrophy Type IISpinal Muscular Atrophy Type III Non Ambulant
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 165
- Registration Number
- NCT01302600
- Locations
- 🇫🇷
Hôpital Raymond Poincaré, Garches, France
🇫🇷Hôpital Femme-Mère-Enfant, Bron, France
🇩🇪University of Essen, Essen, Germany
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01301729